ENDRA Life Sciences Receives Extension to Regain Nasdaq Continuing Listing Requirements Page 1

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer in Thermo Acoustic Enhanced UltraSound (TAEUS), today announced that on August 27, 2024, the Company was notified by The Nasdaq Stock Market LLC (“Nasdaq”) that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request for an extension until November 20, 2024 to demonstrate compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market.

To regain compliance with the bid price requirement, the Company must demonstrate a closing bid price of at least $1.00 per share for at least 10 consecutive trading sessions on or before November 20, 2024. The Company will consider all available options to timely demonstrate compliance with the terms of the Panel’s decision.